---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056320"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:28:44.138205+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunome reports Q1 2023 net loss of $4.3M; posts $2.4M collaboration revenue from AbbVie deal

## Summary
- Collaboration revenue of $2.4M from AbbVie strategic deal for up to 10 novel antibody-target pairs.
- Net loss of $4.3M for Q1 2023; R&D expenses $3.9M, G&A expenses $2.8M.
- Cash and cash equivalents $44.4M as of March 31, 2023.
- AbbVie deal includes $30M upfront, $70M platform milestones, and up to $120M per target in development/commercial milestones.
- Formed Antibody-Drug Conjugate and T Cell Redirection Advisory Board in February 2023.

## SEC filing metadata
- accession: 0001104659-23-056320
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/0001104659-23-056320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/tm2314520d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056320
- JSON: https://secwatch.observer/filing/0001104659-23-056320.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056320.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported the first quarter ended March 31, 2023 results: revenue $2.4 million, net income $4.3 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $2.4 million
  - Net income: $4.3 million
  - Result: reported results
  source text: including ADCs. Financial Highlights · Collaboration Revenue : Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended March 31, 2023 was $2.4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2023 were $3.9 million. · General and administrative (G&A) expenses: G&A expenses,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/0001104659-23-056320-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.